Volumetric brain MRI quantification, including ARIA (amyloid-related imaging abnormality) monitoring for anti-amyloid Alzheimer’s treatments.
FDA cleared and CE marked; recent extension (NeuroQuant 5.0) specifically for ARIA quantification.
Trade press coverage of the FDA clearance for NeuroQuant 5.0.
Not found in this research pass — verify before publishing.
Not independently quantified in this research pass.
No independent evidence found in this pass, though the ARIA use case is clinically timely and worth a deeper follow-up.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.